One-third of cases of early-stage HCC (tumors <3 cm) are missed using AFP analysis [21], and serum AFP levels are also elevated in patients with benign liver diseases, such as hepatitis and cirrhosis [22], [23]. This evidence concerns the gene AFP and hepatitis A virus infection.